Delivery Order SPE2DB20D2104-SPE2DB23FT90J
- Not listed
- This federal contract award, valued at $9,555.42, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a delivery order (SPE2DB20D1100|SPE2DB24FA4P3) for the pharmaceutical product BIKTARVY 50-200-25 MG TABLET UU 30S, with a completion date of February 29, 2024. The contract is a firm fixed-price arrangement and was awarded without any set-aside designation, indicating open competition. Amerisourcebergen Drug Corp, a major...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a Firm Fixed Price Delivery Order worth $76,466.38 awarded by the Defense Logistics Agency (DLA). The contract is for the delivery of BIKTARVY 50-200-25 MG TABLET, a pharmaceutical product, and has an ultimate completion date of March 1, 2022. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running...
- This federal contract award, valued at $17,632.58, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of BIKTARVY 50-200-25 MG TABLET, a prescription medication, with a completion date of January 12, 2024. The contract is a delivery order with a firm fixed price pricing type and does not have a set-aside designation, indicating open competition. Amerisourcebergen...
- This federal contract award is to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of BIKTARVY 50-200-25 MG TABLET to the Defense Logistics Agency (DLA). The award, valued at $97,947.83, is a Firm Fixed Price Delivery Order contract with a completion date of September 3, 2021. Amerisourcebergen Drug Corp is a subsidiary of the parent company, Cencora, Inc., which is also registered as a federal contractor. The contract does not have a set-aside designation,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $58,116.92 firm fixed-price delivery order is for the supply of BIKTARVY 50-200-25 MG TABLET UU 30S, a prescription medication. The contract has an ultimate completion date of February 8, 2023. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a significant...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $29,351.69, is for the delivery of the pharmaceutical product BIKTARVY 50-200-25 MG TABLET in units of 30. The contract has a completion date of March 13, 2024 and is a Firm Fixed Price Delivery Order with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is a subsidiary...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order worth $54,991.16 for the supply of BIKTARVY 50-200-25 MG TABLET. The award was made by the Defense Logistics Agency (DLA), a defense agency, and has a completion date of March 11, 2024. The contract is a firm-fixed-price delivery order with no set-aside designation, indicating full and open competition. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that holds...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract is a Delivery Order valued at $7,525.83 for the supply of BIKTARVY 50-200-25 MG TABLET UU 30S, a pharmaceutical product. The contract has an ultimate completion date of May 1, 2024 and is a Firm Fixed Price arrangement. Amerisourcebergen Drug Corp holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a $80,094.40 Firm Fixed Price Delivery Order issued by the Defense Logistics Agency (DLA) for the pharmaceutical product BIKTARVY 50-200-25 MG TABLET. The contract has an ultimate completion date of August 16, 2022 and was awarded on August 15, 2022. It is not designated as a set-aside contract. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The $13,078.93 firm fixed-price delivery order is for the supply of BIKTARVY 50-200-25 MG TABLET medication. The contract has a completion date of June 24, 2024 and is not designated as a set-aside. Amerisourcebergen holds a larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FT90JDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The $14,988.37 firm-fixed-price delivery order is for the supply of the pharmaceutical product BIKTARVY 50-200-25 MG TABLET UU 30S, with a completion date of June 9, 2023. The contract is not designated with a set-aside requirement, indicating open competition. Amerisourcebergen, a major pharmaceutical distributor, holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and other critical medical commodities, to support military and veteran healthcare programs globally. Additionally, Amerisourcebergen holds a separate $750,000.00 IDC with the Department of Justice Federal Bureau of Investigation for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $15.0k | 6/8/23 |